Chen Y Q, Rafi M A, de Gala G, Wenger D A
Department of Medicine (Medical Genetics), Thomas Jefferson University, Jefferson Medical College, Philadelphia, PA 19107.
Hum Mol Genet. 1993 Nov;2(11):1841-5. doi: 10.1093/hmg/2.11.1841.
Globoid cell leukodystrophy (Krabbe disease) is an autosomal recessive disorder resulting from the deficiency of galactocerebrosidase (GALC) activity. GALC is responsible for the lysosomal catabolism of galactosylceramide, a major lipid in myelin, kidney and epithelial cells of small intestine and colon. We describe the molecular cloning of human GALC cDNA and its expression in COS-1 cells. Degenerate PCR primers, derived from N-terminal amino acid sequence from the 51 kDa band from human brain, were used to amplify cat testes RNA, and the resulting product was used to screen human testes and brain libraries. Two overlapping clones contained the total protein coding region, while additional clones and PCR amplification were needed to obtain the complete 3' end of the cDNA. The 3795 bp obtained include 47 bp 5' to the initiation start site, 2007 bp of open reading frame (coding for 669 amino acids), and 1741 bp of 3' untranslated sequence. Modification of the sequence surrounding the initiation codon to one more favorable for expression, resulted in a 6-fold increase in GALC activity in transfected COS-1 cells. The isolation of this clone will permit investigations into the causes for GALC deficiency in humans and available animal models, development of more accurate tests for patient and carrier identification, and evaluation of methods for effectively treating GALC deficiency, initially using the animal models.
球状细胞脑白质营养不良症(克拉伯病)是一种常染色体隐性疾病,由半乳糖脑苷脂酶(GALC)活性缺乏所致。GALC负责髓磷脂、肾脏以及小肠和结肠上皮细胞中主要脂质半乳糖神经酰胺的溶酶体分解代谢。我们描述了人GALC cDNA的分子克隆及其在COS-1细胞中的表达。根据人脑51 kDa条带的N端氨基酸序列设计简并PCR引物,用于扩增猫睾丸RNA,所得产物用于筛选人睾丸和脑文库。两个重叠克隆包含了完整的蛋白质编码区,而获得cDNA完整的3'端还需要其他克隆和PCR扩增。获得的3795 bp包括起始位点上游5'端的47 bp、2007 bp的开放阅读框(编码669个氨基酸)以及1741 bp的3'非翻译序列。将起始密码子周围的序列修饰为更有利于表达的序列,使转染的COS-1细胞中GALC活性提高了6倍。该克隆的分离将有助于研究人类和现有动物模型中GALC缺乏的原因,开发更准确的患者和携带者检测方法,并首先利用动物模型评估有效治疗GALC缺乏的方法。